HR 9583
Healthy Mothers, Healthy Babies Act of 2026
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
119th CONGRESS — 2d Session
H. R. 9583
IN THE HOUSE OF REPRESENTATIVES
A BILL
To provide support for scaling up global access to multiple micronutrient supplements and other cost effective maternal and child interventions, and for other purposes.
This Act may be cited as the Healthy Mothers, Healthy Babies Act of 2026
.
Congress finds the following:
Investments in effective programs to prevent maternal and child deaths directly advance United States foreign policy and economic interests by promoting stability, increased economic growth and market access and improved diplomatic relations with partner countries.
Global maternal and child deaths remain unacceptably high. In 2023, a woman died of pregnancy related causes every 2 minutes. Millions of children under 5 continue to die every year from preventable causes, with preterm birth, birth complications, and childhood diseases, like pneumonia and diarrhea, accounting for more than half of all under-5 deaths worldwide.
These deaths are largely preventable through proven, low-cost interventions such as—
skilled care before, during, and after birth;
treatment of childhood infectious diseases;
adequate nutrition for pregnant women and children; and
immunization.
Immunization is a cornerstone of child survival, protecting children from deadly diseases, including diarrheal disease, pneumonia, measles, polio, diphtheria, pertussis, and meningitis. It remains one of the most cost-effective interventions, delivering a return of at least $26 for every $1 invested. The United States Government’s partnership with Gavi, the Global Vaccine Alliance, is a major driver in reducing the number of childhood deaths from vaccine preventable diseases in lower-income countries, with Gavi’s immunization campaigns averting nearly 21,000,000 child deaths since 2000.
Continued United States leadership in maternal and child health could help save millions more lives by 2030, accelerating progress toward ending preventable child and maternal deaths worldwide.
At just $4 per pregnancy, multiple micronutrient supplement (MMS) prenatal vitamins combine 15 essential vitamins and minerals into a single, lifesaving tablet, dramatically improving birth outcomes and reducing maternal anemia.
Despite the immense benefits, most women around the world lack access to modern prenatal vitamins.
Previous guidance from the MMS Global Investment Roadmap suggests that there are at least 260,000,000 pregnant women in high-burden countries who lack access to MMS prenatal vitamins, and providing access for these women to MMS over the next 5 years would save 600,000 lives, improve birth outcomes for 5,000,000 babies, and prevent anemia in over 15,000,000 pregnant women.
20 years of research and 70 rigorous trials prove modern MMS prenatal vitamins are superior to iron-folic acid tablets in every way-slashing low birthweight by an extra 79 percent, stillbirths by 27 percent, and infant deaths by 29 percent.
A coalition of philanthropies has come together to commit $250,000,000 to MMS prenatal vitamins, providing leverage to United States Government investments.
MMS prenatal vitamins are American-made, supporting American factory jobs, and highlighting American ingenuity and compassion.
The following shall be the policy of the United States:
To advance foreign policy, national security and economic interests, by strategically supporting partner countries to invest in maternal and child survival and health programs. The United States shall make maternal and child survival a key objective of United States global health and foreign assistance strategies and programs.
To support programs that reduce preventable death among mothers, newborns, and children and enable them to thrive, which promotes more stable and prosperous societies and advances the United States diplomatic and commercial position with partner countries. United States assistance programs for maternal and child health shall seek to—
reduce preventable child and maternal mortality in priority countries to 12 percent or lower of total deaths by 2030; and
increase coverage levels for the target set of life-saving interventions listed in subsection 4 within 10 to 15 priority countries to a level of at least 70 percent by 2030.
To prioritize scaling up investments in the procurement and delivery of MMS prenatal vitamins as a highly cost-effective intervention to address maternal and child health and malnutrition.
To prioritize the highest impact prevention and treatment interventions targeted towards prenatal, delivery, postnatal, newborn and child care, including prevention and management of complications and infections during pregnancy, access to skilled birth attendants, breastfeeding support, care of small or sick newborns, screening and treatment for malnutrition, vitamin A and other micronutrient supplements, child immunization, and treatments for childhood diseases including diarrhea and pneumonia.
The selection of priority countries shall be based on the following:
The prevalence of malnourished pregnant and lactating women and children under the age of 5.
The presence of high-need, underserved, marginalized, vulnerable, or impoverished communities.
The enabling environment for improved maternal and child health, including presence of national maternal and child health plans and demonstration of strong political commitment.
The report required by paragraph (1) shall include the following:
A summary of progress made towards achieving increased coverage levels for MMS.
A detailed summary of the criteria used in selecting priority countries for receiving MMS prenatal vitamins.
In priority countries—
a detailed summary of MMS scale up programs and activities in the previous fiscal year, including a breakdown of the countries to which resources have been allocated and an estimated number of pregnant women reached with MMS coverage; and
a description of the coordination of MMS programs with other health and development programs.
A description of other donor country and host country financial commitments and efforts to increase MMS coverage, and how the United States is engaging with donor country and host country governments to increase those commitments and efforts along with other interventions to improve nutrition outcomes.
An identification of constraints on implementation of programs and activities and lessons learned from programs and activities from the previous fiscal years.
A summary of how United States assistance programs to increase MMS coverage levels have advanced United States foreign policy and national security priorities with partner countries.
Program funding allocations and obligations disaggregated by country and by program area intervention on an annual basis.
Baseline data for the 2 fiscal years preceding the date of enactment, including funding levels, performance indicators, and programmatic outcomes.
A plan for how priority interventions will be delivered and implemented, ensuring interventions are reaching mothers and children.
A standard set of performance and outcome indicators for maternal and child health programs.
A common set budget tags or codes, consistent across United States agencies and programs, to track funding allocations and obligations by country, year, and intervention area.
In this Act, the term relevant foreign assistance agency means the department or agency designated as primarily responsible for implementing United States foreign assistance under part I of the Foreign Assistance Act of 1961 (22 U.S.C. 2151 et seq.).